

10/506579

DT15 d PCT/PTO 0 2 SEP 2004

PATENT

ATTORNEY DOCKET NUMBER: 50125/097001

## Certificate of Mailing

Date of Deposit: September 2, 2004

Label Number: EV293693832US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jörg Stürzebecher et al. Art Unit:  
Serial No.: Not yet assigned Examiner:  
Filed: September 2, 2004 Customer No.: 21559  
Title: UROKINASE INHIBITORS, PRODUCTION AND USE THEREOF

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed with the application.

**DTIC C'd PCT/PTO C 2 SEP 2004**

03-2095.

Respectfully submitted,

Date: 2 September 2004

~~Karen L. Elbing, Ph.D.~~  
~~Reg. No. 35,238~~

**Clark & Elbing LLP**  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

F:\50125\50125.097001 Information Disclosure Statement filed with app.doc

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))			Attorney Docket No. 50125/097001  Serial No. Not yet assigned  Applicant Jörg Stürzebecher et al.  Filing Date September 2, 2004  Group Not yet assigned  IDS Filed September 2, 2004			
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	6,586,405 B2	07/01/03	Semple et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 02/14349 A2	02/21/02	PCT			
	WO 01/96286 A2	12/20/01	PCT			
	WO 01/81314 A1	11/01/01	PCT			
	WO 00/05245	02/03/00	PCT			
	WO 99/05096	02/04/99	PCT			
	WO 95/17885	07/06/95	PCT			
	DE 10029014 A1	12/20/01	Germany			
	EP 0 183 271	06/04/86	Europe			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Baker et al., "Inhibition of Cancer Cell Urokinase Plasminogen Activator by Its Specific Inhibitor PAI-2 and Subsequent Effects on Extracellular Matrix Degradation," <i>Cancer Research</i> 50:4676-4684 (1990).					
	Cajot et al., "Plasminogen-Activator Inhibitor Type 1 is a Potent Natural Inhibitor of Extracellular Matrix Degradation by Fibrosarcoma and Colon Carcinoma Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6939-6943 (1990).					
	Dixon, "The Determination of Enzyme Inhibitor Constants," <i>Biochem. J.</i> 55:170-171 (1953).					
	Duggan et al., "Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Breast Cancer," <i>Int. J. Cancer</i> 61:597-600 (1995).					
	Judkins et al., "A Versatile Synthesis of Amidines from Nitriles Via Amidoximes," <i>Synthetic Communications</i> 26:4351-4367 (1996).					
	Kettner et al., "Inactivation of Trypsin-Like Enzymes with Peptides of Arginine Chloromethyl Ketone," <i>Methods in Enzymology</i> 80:826-843 (1981).					
	Krüger et al., "Host TIMP-1 Overexpression Confers Resistance to Experimental Brain Metastasis of a Fibrosarcoma Cell Line," <i>Oncogene</i> 16:2419-2423 (1998).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	<table border="1"> <tr> <td>Attorney Docket No.</td> <td>50125/097001</td> </tr> <tr> <td>Serial No.</td> <td>Not yet assigned</td> </tr> <tr> <td>Applicant</td> <td>Jörg Stürzebecher et al.</td> </tr> <tr> <td>Filing Date</td> <td>September 2, 2004</td> </tr> <tr> <td>Group</td> <td>Not yet assigned</td> </tr> <tr> <td>IDS Filed</td> <td>September 2, 2004</td> </tr> </table>	Attorney Docket No.	50125/097001	Serial No.	Not yet assigned	Applicant	Jörg Stürzebecher et al.	Filing Date	September 2, 2004	Group	Not yet assigned	IDS Filed	September 2, 2004
Attorney Docket No.	50125/097001												
Serial No.	Not yet assigned												
Applicant	Jörg Stürzebecher et al.												
Filing Date	September 2, 2004												
Group	Not yet assigned												
IDS Filed	September 2, 2004												
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)													
	Krüger et al., "The Bacterial <i>LacZ</i> Gene: An Important Tool for Metastasis Research and Evaluation of New Cancer Therapies," <i>Cancer and Metastasis Reviews</i> 17:285-294 (1999).												
	Künzel et al., "4-Aminobenzylamine-Based Inhibitors of Urokinase," <i>Biorganic &amp; Medicinal Chemistry Letters</i> 12:645-648 (2002).												
	Mignatti et al., "Biology and Biochemistry of Proteinases in Tumor Invasion," <i>Physiological Reviews</i> 73:161-195 (1993).												
	Ossowski et al., "Antibodies to Plasminogen Activator Inhibit Human Tumor Metastasis," <i>Cell</i> 35:611-619 (1983).												
	Pedersen et al., "Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue," <i>Cancer Research</i> 54:4671-4675 (1994).												
	Reuning et al., "Multifunctional Potential of the Plasminogen Activation System in Tumor Invasion and Metastasis (Review)," <i>International Journal of Oncology</i> 13:893-906 (1998).												
	Schechter et al., "On the Size of the Active Site in Proteases," <i>Biochemical and Biophysical Research Communications</i> , 27:157-162 (1967).												
	Schmitt et al., "Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy," <i>Thrombosis and Haemostasis</i> 78:285-296 (1997).												
	Sperl et al., "(4-Aminomethyl) Phenylguanidine Derivates as Nonpeptidic Highly Selective Inhibitors of Human Urokinase," <i>PNAS</i> 97:5113-5118 (2000).												
	Stephens et al., "The Urokinase Plasminogen Activator System as a Target for Prognostic Studies in Breast Cancer," <i>Breast Cancer Research and Treatment</i> , 52:99-111 (1998).												
	Stürzebecher et al., "3-Amidinophenylalanine-Based Inhibitors of Urokinase," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 9:3147-3152 (1999).												
	Stürzebecher et al., "Synthesis and Structure -Activity Relationships of Potent Thrombin Inhibitors: Piperazides of 3-Amidinophenylalanine," <i>J. Med. Chem.</i> 40:3091-3099 (1997).												
	Stürzebecher et al., "Synthetische Inhibitoren der Serinproteinasen," <i>Pharmazie</i> 33:599-602 (1978).												
	Sucker et al., "Pharm. Techn. 2.," Bauer, Georg Thieme Verlag, Stuttgart, 1991.												
	Tamura et al., "Synthesis and Biological Activity of Peptidyl Aldehyde Urokinase Inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 10:983-987 (2000).												
	Towle et al., "Inhibition of Urokinase by 4-Substituted Benzo[b]thiophene-2-Carboxamides: An Important New Class of Selective Synthetic Urokinase Inhibitor," <i>Cancer Research</i> 53:2553-2559 (1993).												
EXAMINER	DATE CONSIDERED												
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.													

10/506579

DT11 Rec'd PCT/PTO 02 SEP 2004

Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50125/097001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))				Serial No.	Not yet assigned
				Applicant	Jörg Stürzebecher et al.
				Filing Date	September 2, 2004
				Group	Not yet assigned
				IDS Filed	September 2, 2004
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
	Vassalli et al., "Amloride Selectively Inhibits the Urokinase-Type Plasminogen Activator," <i>FEB</i> 214:187-191 (1987).				
	Zeslowska et al., "Crystals of Urokinase Type Plasminogen Activator Complexes Reveal the Binding Mode of Peptidomimetic Inhibitors," <i>J. Mol. Biol.</i> 328:109-118 (2003).				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					